The XXB750 clinical trial represents a step forward in the treatment of resistant hypertension. The study was sponsored by Novartis Pharmaceuticals and aimed to evaluate the efficacy, safety, and tolerability of XXB750, a new medication with a potential to help those with treatment-resistant hypertension.
Overview
The XXB750 trial was a 20-week randomized double-blind study that included patients with resistant hypertension (rHTN). These patients were already on maximally tolerated background antihypertensive therapy as recommended by international guidelines. The study’s goal was to determine the effectiveness of different doses of XXB750 compared to a placebo.
Results
The trial participants received three doses of the study medication over 12 weeks, followed by an 8-week safety follow-up period. The results indicated overall safety and good tolerability of XXB750, with peak times at 4-10 days and a half-life of 15-25 days at doses ≥60 mg. This suggests that XXB750 could be a promising new treatment for those with resistant hypertension, offering a new avenue for managing this challenging condition.
NHI participated in this trial and is currently enrolling patients in other clinical trials.
Clinical trials offer significant potential benefits to patients:
Access to New Treatments: Trial participants have the opportunity to receive new treatments before they are widely available to the public.
High-Quality Medical Care: Trial participants receive care from NHI’s dedicated research team who are very knowledgeable about the latest treatments and work with the participants’ other healthcare providers to ensure patient safety.
Active Role in Personal Healthcare Management: By participating in clinical trials, patients can play a proactive role in their own healthcare, choose cutting-edge treatments that may benefit them over existing treatments, and contribute to the advancement of medical knowledge.
NHI CLINICAL TRIALS ARE FREE AND YOU WILL BE PAID FOR YOUR PARTICIPATION!
Visit www.nationalheartinstitute.org to learn more and to explore other clinical trials that are currently enrolling.
